Jane McGuffog has over 30 years of experience in Drug Discovery and Development. She brings extensive expertise across the pharmaceutical R&D spectrum, with roles at companies including Parke Davis, Pfizer, Millennium Pharmaceuticals and Proximagen. In her last 7 years at BenevolentAI, she led DMPK, Safety, and Modelling functions, while also managing projects through Phase I and Phase II clinical development. Her deep knowledge spans DMPK, PBPK, and Translational Science, underpinned by a strong track record of project and people leadership.
At Quotient Sciences, she heads a seasoned team of modellers dedicated to advancing drug development through the application of Physiologically Based Biopharmaceutics Modelling (PBBM) and Physiologically Based Pharmacokinetic Modelling (PBPK)
She holds a BSc (Hons) in Applied Chemistry from the University of Portsmouth.
VIDEO: Modeling & simulation at Quotient Sciences
Learn how modeling and simulation help advance drug programs more efficiently. Jane discusses how modeling can support virtual bioequivalence assessments, optimize DDI study strategies, and potentially reduce the need for additional clinical work.
Additionally, Jane highlights how we are using Ai and a collaboration with Intrepid Laboratories to go even futher.
